In a retrospective study of patients with erosive RA conducted by Laroche et al., RTX was administered more often in patients with sSS, diagnosed based on salivary gland biopsy findings, positivity of anti-Ro/SS-A antibodies, or both, compared to patients without sSS. The gene discussed is RO60; the disease is rheumatoid arthritis.